|
|
|
| Progress on the molecular mechanism of delamanid and PA-824 resistance in Mycobacterium tuberculosis |
| WANG Xiao-ying1, LUO Ming2, LI Jun-gang2, ZHANG Hui-zheng2 |
1. Chongqing Medical and Pharmaceutical College, Chongqing 401331, China;
2. Chongqing Public Health Medical Center, Chongqing 400036, China |
|
|
|
|
Abstract Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) is still one of the top ten causes of death in the world, especially with the presence of drug resistant tuberculosis, which has caused great challenges for tuberculosis control. Both delamanid and PA-824 (Pretomanid) are nitroimidazole anti-TB drugs that have had a good effectiveness in the treatment of multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis. Furthermore, the BPaL regimen that consists of PA-824, bedaquiline and linezolid, has a better cure rate for highly drug resistant TB cases. However, MTB with resistance to delamanid and PA-824 have been observed in recent years. Rapid examination of MTB resistance to delamanid and PA-824 could effectively avoid the aggravation of drug resistance and improve their clinical application. This study reviewed the resistance related genes of MTB to delamanid and PA-824, in order to provide a reference for the rapid diagnosis of drug resistance to delamanid and PA-824 in MTB and for their continued application in clinical treatment.
|
|
Received: 28 November 2021
|
|
|
|
Corresponding Authors:
Zhang Hui-zheng, Email: zhz200402@126.com
|
|
|
|
[1] World Health Organization.Global tuberculosis report 2021[R]. Geneva: World Health Organization,2021.
[2] World Health Organization.WHO consolidated guidelines on drug-resistant tuberculosis treatment[M]. Geneva: World Health Organization, 2019.
[3] Oelofse S, Esmail A, Diacon AH, et al.Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts[J]. Int J Tuberc Lung Dis, 2021, 25(6):453-460. DOI: 10.5588/ijtld.21.0035
[4] Matsumoto M, Hashizume H, Tomishige T, et al.OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice[J]. PLoS Med, 2006, 3(11): e466. DOI: 10.1371/ journal.pmed.0030466
[5] Yuan Y, Zhu Y, Crane DD, et al.The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis[J]. Mol Microbiol, 1998, 29(6):1449-1458. DOI: 10.1046/j. 1365-2958.1998.01026.x
[6] Xavier AS, Lakshmanan M.Delamanid: a new armor in combating drug-resistant tuberculosis[J]. J Pharmacol Pharmacother, 2014, 5(3): 222-224. DOI: 10.4103/0976-500X.136121
[7] Manjunatha UH, Boshoff H, Dowd CS, et al.Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis[J]. Proc Natl Acad Sci U S A,2006,103(2):431-436. DOI: 10.1073/pnas.0508392103
[8] Choi KP, Bair TB, Bae YM, et al.Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F420 biosynthesis by Mycobacterium bovis BCG[J]. J Bacteriol, 2001, 183(24): 7058-7066. DOI: 10.1128/JB.183.24.7058-7066.2001
[9] Choi KP, Kendrick N, Daniels L.Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F420 and FO biosynthesis[J]. J Bacteriol, 2002, 184(9): 2420-2428. DOI:10.1128/JB.184.9.2420-2428.2002
[10] Singh R, Manjunatha U, Boshoff HIM, et al.PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release[J]. Science, 2008, 322(5906): 1392-1395. DOI: 10.1126/science.1164571
[11] Rifat D, Li SY, Ioerger T, et al.Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2020, 65(1): e01948-20. DOI: 10.1128/AAC.01948-20
[12] Haver HL, Chua A, Ghode P, et al.Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2015, 59: 5316-5323. DOI: 10.1128/AAC. 00308-15
[13] Fujiwara M, Kawasaki M, Hariguchia N, et al.Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis[J]. Tuberculosis (Edinb), 2018, 108: 186-194. DOI: 10.1016/j.tube.2017.12.006
[14] Denny WA, Palmer, Brian D.The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies[J]. Future Med Chem, 2010, 2(8): 1295-1304. DOI: 10.4155/fmc.10.207
[15] Liu Y, Matsumoto M, Ishida H, et al.Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)[J]. Tuberculosis (Edinb), 2018, 111:20-30. DOI: 10.1016/j.tube.2018.04.008
[16] Schena E, Nedialkova L, Borroni E, et al.Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system[J]. J Antimicrob Chemother, 2016, 71(6):1532-1539. DOI: 10.1093/jac/dkw044
[17] Zheng H, He W, Jiao W, et al.Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China[J]. BMC Infect Dis, 2021, 21(1): 330. DOI: 10.1186/s12879-021-06024-8
[18] Feuerriegel S, Köser CU, Baù D, et al.Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824[J]. Antimicrob Agents Chemother, 2011, 55(12): 5718-5722. DOI: 10.1128/AAC.05500-11
[19] Kidwai S, Park CY, Mawatwal S, et al.Dual mechanism of action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2017, 61(11): e00969-17. DOI: 10.1128/AAC. 00969-17
[20] Lee BM, Harold LK, Almeida DV, et al.Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering[J]. PLoS Pathog, 2020, 16(2): e1008287. DOI: 10.1371/journal.ppat.1008287
[21] Quoc-Thai Nguyen, Gianluca Trinco1, Claudia Binda, et al. Discovery and characterization of an F420-dependent glucose-6-phosphate dehydrogenase (Rh-FGD1) from Rhodococcus jostii RHA1[J]. Appl Microbiol Biotechnol, 2017, 101(7):2831-2842. DOI: 10.1007/s00253-016-8038-y
[22] Bloemberg GV, Keller PM, Stucki D, et al.Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis[J]. N Engl J Med, 2015, 373(20): 1986-1988. DOI: 10.1056/NEJMc1505196
[23] Forouhar F, Abashidze M, Xu H, et al.Molecular insights into the biosynthesis of the F420 coenzyme[J]. Biol Chem, 2008, 283(17):11832-11840. DOI: 10.1074/jbc.M710352200
[24] Hoffmann H, Kohl TA, Hofmann-Thiel S, et al.Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee[J]. Am J Respir Crit Care Med, 2016, 193(3): 337-340. DOI: 10.1164/rccm.201502-0372LE
[25] Battaglia S, Spitaleri A, Cabibbe AM, et al.Characterization of genomic variants associated with resistance to bedaquiline and delamanid in naive Mycobacterium tuberculosis clinical strains[J]. J Clin Microbiol, 2020, 58(11):e01304-20. DOI: 10.1128/JCM.01304-20
[26] Bashiri G, Rehan AM, Sreebhavan S, et al.Elongation of the poly-gamma-glutamate tail of F420 requires both domains of the F420: gamma-glutamyl ligase (FbiB) of Mycobacterium tuberculosis[J]. Biol Chem, 2016, 291(13): 6882-6894. DOI: 10.1074/jbc.M115.689026
[27] Nieto Ramirez LM, Quintero Vargas K, Diaz G.Whole genome sequencing for the analysis of drug resistant strains of Mycobacterium tuberculosis: a systematic review for bedaquiline and delamanid[J]. Antibiotics (Basel), 2020, 9(3): 133. DOI: 10.3390/antibiotics9030133
[28] Pang Y, Zong Z, Huo F, et al.In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China[J]. Antimicrob Agents Chemother, 2017,61(10): e00900-17. DOI: 10.1128/AAC.00900-17 |
|
|
|
2022, Vol. 38 
